Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Epistemonikos ID: c1fd3cd3b615252004cb15d82accf2a42d3d3173
First added on: Jul 28, 2026